The FDA’s finalized guidance on Scientific Information on Unapproved Uses (SIUU) marks a pivotal shift for pharmaceutical companies—offering new clarity and flexibility for engaging healthcare providers in compliant, science-based dialogue.
In this POV, EVERSANA’s Oncology experts explore how to align strategy with compliance while maximizing the impact of data across a variety of scientifically sound sources. Inside this POV, you’ll uncover:
- How the FDA’s final SIUU guidance changed the rules of engagement
- How companies are rethinking rep protocols, booth design, and digital tools
- What drugs may see a surge in interest for scientific information about unapproved uses
Access the full POV to explore actionable strategies, real-world examples, and how EVERSANA can help your brand lead with credibility.
Author
Anne Marie is helping EVERSANA deliver value to stakeholders across the life sciences industry. Through her multi-decade career at prominent large and small pharmaceutical companies, she has become a proven biopharma leader driving cross-functional…
Tim has served as a strategic lead to healthcare companies for more than 25 years in advertising, marketing, and finance roles in agency and client settings. His work spans pre-clinical to sunset strategies and from brand infrastructure to digital roadmaps. He has helped stand up clinical trial…
Susan leads field medical efforts for EVERSANA. As a leader in the life sciences industry, she brings more than 20 years of medical affairs experience across multiple therapeutic areas, including oncology, hepatology and rare…